Case-control study of aspirin use and risk of pancreatic cancer.
Case-control study of aspirin use and risk of pancreatic cancer.
复制标题
阿司匹林使用和胰腺癌风险的病例对照研究。
DOI：
10.1158/1055-9965.epi-13-1284
复制
发表时间：
2014-07
期刊：
影响因子：
--
通讯作者：
Risch HA
中科院分区：
文献类型：
--
作者：
Streicher SA;Yu H;Lu L;Kidd MS;Risch HA
胰腺癌的预后很差，5年生存率不到5%。13项研究中有4项显示阿司匹林的使用与胰腺癌发病率和死亡率降低之间存在显著关系。为了进一步评估阿司匹林使用与胰腺癌风险之间的可能关联，我们使用了2005年1月至2009年8月进行的基于人群的康涅狄格州研究的数据，其中362例胰腺癌病例频率与690例随机抽样对照相匹配。总体而言，定期使用阿司匹林与胰腺癌风险降低相关（比值比[OR]，0.52; 95%CI，0.39-0.69）。在低剂量或常规剂量阿司匹林使用的每一年中，胰腺癌风险降低的幅度都有所增加（OR，0.94; 95%CI，0.91-0.98和OR，0.98; 95%CI，0.96-1.01）和过去开始使用低剂量或常规剂量阿司匹林的年份增加（OR，0.95; 95%CI，0.92-0.99和OR，0.98; 95%CI，0.96-1.00）。在大多数阿司匹林使用日历时间段的类别中，无论是低剂量阿司匹林还是常规剂量阿司匹林，都可以降低胰腺癌的风险。与随访时继续使用阿司匹林相比，随访2年内停用阿司匹林与胰腺癌风险增加相关（OR，3.24; 95%CI，1.58-6.65）。我们的研究结果提供了一些支持，每天服用阿司匹林可以降低患胰腺癌的风险。长期使用阿司匹林对心血管疾病和癌症都有好处，但明显的出血并发症需要对个体应用进行风险效益分析。
Pancreas-cancer prognosis is dismal, with 5-year survival less than 5%. Significant relationships between aspirin use and decreased pancreas-cancer incidence and mortality have been shown in four of 13 studies. To evaluate further a possible association between aspirin use and risk of pancreatic cancer, we used data from a population-based Connecticut study conducted from January 2005-August 2009, of 362 pancreas-cancer cases frequency matched to 690 randomly sampled controls. Overall, regular use of aspirin was associated with reduced risk of pancreatic cancer (odds ratio [OR], 0.52; 95% CI, 0.39–0.69). Increments of decreasing risk of pancreatic cancer were observed for each year of low-dose or regular-dose aspirin use (OR, 0.94; 95% CI, 0.91–0.98 and OR, 0.98; 95% CI, 0.96–1.01, respectively) and for increasing years in the past that low-dose or regular-dose aspirin use had started (OR, 0.95; 95% CI, 0.92–0.99 and OR, 0.98; 95% CI, 0.96–1.00, respectively). Reduced risk of pancreatic cancer was seen in most categories of calendar time period of aspirin use, for both low-dose aspirin and regular-dose aspirin use. Relative to continuing use at the time of interview, termination of aspirin use within 2 years of interview was associated with increased risk of pancreatic cancer (OR, 3.24; 95% CI, 1.58–6.65). Our results provide some support that a daily aspirin regimen may reduce risk of developing pancreatic cancer. Long-term aspirin use has benefits for both cardiovascular disease and cancer, but appreciable bleeding complications that necessitate risk-benefit analysis for individual applications.